



NIH AIDS Reagent Program

20301 Century Boulevard
Building 6, Suite 200
Germantown, MD 20874
USA

Phone: 240 686 4740
Fax: 301 515 4015
aidsreagent.org

DATA SHEET

Reagent:	☒ HIV-1 RF/V82F/184V Virus
Catalog Number:	2802
Lot Number:	110236
Release Category:	A
Provided:	1 mL cell-free virus TCID ₅₀ = 1.0 x 10 ⁵ /mL. p24 = 200 ng/mL
Host Strain:	MT-2 cells
Sterility:	Negative for mycoplasma, bacteria and fungi.
Description:	HIV-1 Protease mutant derived from HIV-1 RF strain.
Special Characteristics:	Single and double protease gene mutant strains were selected <i>in vitro</i> in the presence of the novel protease inhibitors DMP323 (a cyclic urea protease inhibitor) or P9941 (a C-2 symmetrical diol protease inhibitor). Four mutants derived from HIV-1 _{RF} and one from the AZT-resistant strain Donor E are available. All of those viruses are stable in culture, and do not require the addition of antivirals to maintain phenotype. All are extremely cytopathic and require frequent feeding with uninfected cells. Table of additional HIV-1 Protease mutants included in this set.
Recommended Storage:	Liquid nitrogen.
Contributor:	Dr. Dean Winslow.

ALL RECIPIENTS OF THIS MATERIAL MUST COMPLY WITH ALL APPLICABLE BIOLOGICAL, CHEMICAL, AND/OR RADIOCHEMICAL SAFETY STANDARDS INCLUDING SPECIAL PRACTICES, EQUIPMENT, FACILITIES, AND REGULATIONS. NOT FOR USE IN HUMANS.

References:

Otto MJ, Garber S, Winslow D, Reid CD, Aldrich P, Jadhav PK, Patterson CE, Hoge CN, Cheng YS. *In vitro* isolation and identification of HIV variants with reduced sensitivity to C-2 symmetrical inhibitors of HIV-1 protease. *Proc Natl Acad Sci USA* **90**:7543-7547, 1993.

ALL RECIPIENTS OF THIS MATERIAL MUST COMPLY WITH ALL APPLICABLE BIOLOGICAL, CHEMICAL, AND/OR RADIOCHEMICAL SAFETY STANDARDS INCLUDING SPECIAL PRACTICES, EQUIPMENT, FACILITIES, AND REGULATIONS. NOT FOR USE IN HUMANS.

King RW, Garber S, Winslow DL, Reid C, Bacheler LT, Anton E, Otto MJ. Multiple mutations in the human immunodeficiency virus protease gene are responsible for decreased susceptibility to protease inhibitors. *Antiviral Chem Chemother* **6**:80-88, 1995.

Otto MJ, Reid CD, King RW, Garber S, Baker DB, Anton E, Winslow DL. Exposure of chronically infected PBMC's to DMP450 can completely suppress virus replication or select resistant variants depending upon the dose of compound. *Second National Conference on Human Retroviruses and Related Infections*, Washington, DC, January 29-February 2, 1995.

NOTE: Acknowledgment for publications should read "The following reagent was obtained through the NIH AIDS Reagent Program, Division of AIDS, NIAID, NIH: (specify virus) from Dr. Dean Winslow." Also include the references cited above in any publications.

Last Updated: July 31, 2018

ALL RECIPIENTS OF THIS MATERIAL MUST COMPLY WITH ALL APPLICABLE BIOLOGICAL, CHEMICAL, AND/OR RADIOCHEMICAL SAFETY STANDARDS INCLUDING SPECIAL PRACTICES, EQUIPMENT, FACILITIES, AND REGULATIONS. NOT FOR USE IN HUMANS.